Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 181 AL 195

[Advance in study on endogenous formaldehyde and pathogenesis of Alzheimer's disease]

Li WW, Guo H, Fan GW, Wang XM.

Zhongguo Zhong Yao Za Zhi. 2012 Oct;37(20):3017-20.

Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease

Christensen DD.

Postgrad Med. 2012 Nov;124(6):110-6. doi: 10.3810/pgm.2012.11.2589.

Review of drugs for Alzheimer's disease

Sun X, Jin L, Ling P.

Drug Discov Ther. 2012 Dec;6(6):285-90.

Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia

Nasab NM, Bahrammi MA, Nikpour MR, Rahim F, Naghibis SN.

J Pak Med Assoc. 2012 Jul;62(7):677-80.

Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia

Neri M, Bonassi S, Russo P.

Curr Drug Targets. 2012 May;13(5):636-43. doi: 10.2174/138945012800398928.

The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease

Carroll JC, Rosario ER.

Curr Alzheimer Res. 2012 Jan;9(1):18-34. doi: 10.2174/156720512799015109.

Higher vitamin D dietary intake is associated with lower risk of alzheimer's disease: a 7-year follow-up

Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B, Herrmann FR, Beauchet O.

J Gerontol A Biol Sci Med Sci. 2012 Nov;67(11):1205-11. doi: 10.1093/gerona/gls107. Epub 2012 Apr 13.

The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design

Andersen F, Viitanen M, Halvorsen DS, Straume B, Wilsgaard T, Engstad TA.

BMC Neurol. 2012 Jul 19;12:59. doi: 10.1186/1471-2377-12-59.

Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis

Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR, Corrigan B.

J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):479-98. doi: 10.1007/s10928-012-9263-3. Epub 2012 Jul 21.

The immunology of traumatic brain injury: a prime target for Alzheimer's disease prevention

Giunta B, Obregon D, Velisetty R, Sanberg PR, Borlongan CV, Tan J.

J Neuroinflammation. 2012 Aug 1;9:185. doi: 10.1186/1742-2094-9-185.

Antioxidant therapies for Alzheimer's disease

Feng Y, Wang X.

Oxid Med Cell Longev. 2012;2012:472932. doi: 10.1155/2012/472932. Epub 2012 Jul 25.

Association between chronic blood pressure changes and development of Alzheimer's disease

Feldstein CA.

J Alzheimers Dis. 2012;32(3):753-63. doi: 10.3233/JAD-2012-120613.

What are the prospects of slowing the progression of Alzheimer's disease?

Palmer AM.

Drug Discov Today. 2012 Nov;17(21-22):1157-9. doi: 10.1016/j.drudis.2012.09.009. Epub 2012 Oct 2.

Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes

Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C.

Drugs Aging. 2012 Oct;29(10):793-806. doi: 10.1007/s40266-012-0012-5.

Estrogens and Alzheimer disease risk: is there a window of opportunity?

Henderson VW, Rocca WA.

Neurology. 2012 Oct 30;79(18):1840-1. doi: 10.1212/WNL.0b013e318271f88f. Epub 2012 Oct 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias